Latest Manufacturing News

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Cycliq Group Limited reported a 3.8% revenue increase to AUD 4.78 million for FY2025 alongside a significant reduction in net loss, driven by strategic product enhancements and a new AI partnership. The company also strengthened its board and launched a revamped e-commerce platform, positioning itself for growth despite ongoing legal and operational risks.

Prestal Holdings reported a sharp 25% revenue decline and a staggering 133% increase in net loss for FY2025, yet still declared a special dividend and capital return.

Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.

Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.

Vmoto Limited reported a 10.8% revenue decline to $20.8 million in H1 2025 but reduced its net loss slightly to $3 million, buoyed by resilient international sales and a strategic partnership with Uber to electrify delivery fleets across Europe.

Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.

First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.